GMED earnings call for the period ending December 31, 2024.

Globus Medical (GMED) delivered earnings and revenue surprises of 10.53% and 2.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro Corp ...

RFG is managed by Invesco, and this fund has amassed over $324.79 million, which makes it one of the average sized ETFs in the Style Box - Mid Cap Growth. This particular fund, before fees and ...

Under the terms of the agreement, Globus Medical will acquire all shares of ... We are a national class action securities firm with a successful track record in trial and appellate courts ...

If you're the kind of investor who would rather try and beat the market through good stock selection, then smart beta funds are your best choice; this fund class is known for tracking non-cap ...

Globus Medical (NYSE:GMED) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.

Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95 and keeps an Overweight rating on the ...

BTIG analyst Ryan Zimmerman raised the firm’s price target on Globus Medical (GMED) to $94 from $91 and keeps a Buy rating on the shares after ...

Globus Medical saw a strong 2024 with multiple new product launches and more innovation is on the way, President and CEO Dan Scavilla said in a Feb. 20 earnings ...